Completed PHASE4 INTERVENTIONAL 2-arm NCT01444469

AZithromycin Against pLacebo in Exacerbations of Asthma (AZALEA)

A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Oral Azithromycin (500 Mg OD) as a Supplement to Standard Care for Adult Patients With Acute Exacerbations of Asthma

Sponsor: Imperial College London

Conditions Asthma

Interventions Placebo Zithromax

Updated 6 times since 2017 Last updated: Jan 8, 2024 Started: Sep 30, 2011 Primary completion: Jun 30, 2014 Completion: Jun 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01444469, this PHASE4 trial focuses on Asthma and remains completed. Sponsored by Imperial College London, it has been updated 6 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Feb 2024 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Feb 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Sep 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Imperial College London
National Institute for Health Research, United Kingdom

Data source: Imperial College London

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barnsley, United Kingdom , Birmingham, United Kingdom , Blackpool, United Kingdom , Glasgow, United Kingdom , Leicester, United Kingdom , Liverpool, United Kingdom , London, United Kingdom , Manchester, United Kingdom , Newcastle, United Kingdom , Nottingham, United Kingdom and 4 more locations